Anti-CANX Polyclonal Antibody | AB0041

Goat Anti-Human CANX IgG Polyclonal Antibody | AB0041 | Antibodies

Overview: Goat polyclonal to CANX (Calnexin) - endoplasmic reticulum (ER) membrane marker. CANX is a member of the calnexin family of molecular chaperones. This protein is a calcium-binding, ER-associated protein that interacts transiently with newly synthesized N-linked glycoproteins, facilitating protein folding and assembly. It may also play a central role in the quality control of protein folding by retaining incorrectly folded protein subunits within the ER for degradation.

Other Names: Calnexin, CALX, CNX, FLJ26570, histocompatibility complex class I antigen binding protein p88, IP90, major histocompatibility complex class I antigen-binding protein p88, MS952, P90 antibody.

Other Names: Calnexin, CALX, CNX, FLJ26570, histocompatibility complex class I antigen binding protein p88, IP90, major histocompatibility complex class I antigen-binding protein p88, MS952, P90 antibody.

Concentration: 2 mg/ml

Antibody Type: Primary

Target Type: Anti-CANX

Accession Number: ENSG00000127022

Host Species: Goat

Immunogen Species: Human

Immunogen Type: Recombinant protein

Immunogen: Purified recombinant peptide within residues 550 aa to the C-terminus of human CANX produced in E. coli.

Isotype: IgG

Clonality: Polyclonal

Confirmed Reactive Species: Human, mouse, rat, bovine, canine, chicken/avian, donkey, feline, goat, guinea pig, hamster, horse, porcine, rabbit, sheep, simian, other

Specificity Detail: Detects a band of 90 kDa by Western blot in the following human (293A, primary fibroblasts, HaCat, HeLa, HMEC-1, Jurkat, MNT1, U-118, rat (TR-iBRB), mouse (3T3, AtT-20, Hepa, Raw264.7), monkey (COS-7) and canine (D17) whole cell lysates.

Buffer: PBS, 20% glycerol and 0.05% sodium azide

Purification: Epitope affinity purified

Conjugation: Unconjugated

Format: N/A

Application: WB, IF, IHC-P, IHC-F

Concentration/Dilution: WB:1:500-1:5,000, IF:1:50-1:500, IHC-P:1:200-1:1,000, IHC-F:1:200-1:1,000

Storage: N/A

References: 1. Catarino S, Ribeiro-Rodrigues TM, Sa Ferreira R, et al. Cells 2020 Apr. PMID: 32272685, 2. Boia R, Dias PAN, Martins JM, et al. J Control Release 2019 Nov. PMID:31715277, 3. Ferreira JV, Rosa Soares A, Ramalho JS, et al. PLoS One. 2019 Oct. PMID:31613922, 4. Sacramento JF, Olea E, Ribeiro MJ, et al. J Physiol 2019 Aug. PMID:31426127, 5. Melo BF, Sacramento JF, Ribeiro MJ, et al. Nutrients 2019 May. PMID:31141900, 6. Sanzà P, Evans RD, Briggs DA, et al. J Cell Sci 2019 Apr. PMID:30898842, 7. Barbeitos JP, MSc Thesis, University of Coimbra, Portugal 2018, 8. Cardoso MHS, PhD Thesis, NOVA University of Lisbon, Portugal 2018, 9. Ribeiro ST, Tesio M, Ribot JC, et al. Leukemia 2017 Jul. PMID:27899804, 10. Pelkonen L, Sato K, Reinisalo M, et al. Mol Pharm 2017 Mar. PMID:28112518, 11. Martins-Marques T, Pinho MJ, Zuzarte M. et al. J Extracell Vesicles 2016 Sep. PMID:27702427, 12. Neves MMM, MSc Thesis, University of Coimbra, Portugal 2015, 13. Ferreira RRS, MSc Thesis, Coimbra University 2015, 14. Paiva RA, MSc Thesis, Coimbra University 2015, 15. Samtleben S, PhD Thesis, Universität Würzburg 2014, 16. Ribot JC, Ribeiro ST, Correia DV, Sousa AE, Silva-Santos B. J Immunol 2014 Mar, PMID: 24489097, 17. Marques, CIR, MSc Thesis, Coimbra University 2013